TPBG

Across TCGA pan-cancer cohorts, TPBG mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TPBG data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TPBG mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TPBG expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where TPBG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.361	0.582	<.001	96	view →
CCRCC	DFS	Median	II,III,IV	0.480	0.753	.011	12	view →
LUAD	OS	Median	II,III,IV	0.429	0.911	.008	10	view →
UCEC	OS	Quartile	II,III,IV	0.530	1.000	.030	8	view →
GBM	DFS	Tertile	All	0.378	0.183	.015	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TPBG–PDAC (OS)

Open the PDAC breakdown →